TY - JOUR
T1 - Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-hispanic white women: The Ovarian Cancer Association Consortium
AU - Phelan, Catherine M.
AU - Tsai, Ya Yu
AU - Goode, Ellen L.
AU - Vierkant, Robert A.
AU - Fridley, Brooke L.
AU - Beesley, Jonathan
AU - Chen, Xiao Qing
AU - Webb, Penelope M.
AU - Chanock, Stephen
AU - Cramer, Daniel W.
AU - Moysich, Kirsten
AU - Edwards, Robert P.
AU - Chang-Claude, Jenny
AU - Garcia-Closas, Montserrat
AU - Yang, Hannah
AU - Wang-Gohrke, Shan
AU - Hein, Rebecca
AU - Green, Adele C.
AU - Lissowska, Jolanta
AU - Carney, Michael E.
AU - Lurie, Galina
AU - Wilkens, Lynne R.
AU - Ness, Roberta B.
AU - Pearce, Celeste Leigh
AU - Wu, Anna H.
AU - Van Den Berg, David J.
AU - Stram, Daniel O.
AU - Terry, Kathryn L.
AU - Whiteman, David C.
AU - Whittemore, Alice S.
AU - DiCioccio, Richard A.
AU - McGuire, Valerie
AU - Doherty, Jennifer A.
AU - Rossing, Mary Anne
AU - Anton-Culver, Hoda
AU - Ziogas, Argyrios
AU - Hogdall, Claus
AU - Hogdall, Estrid
AU - Kjaer, Susanne Krüger
AU - Blaakaer, Jan
AU - Quaye, Lydia
AU - Ramus, Susan J.
AU - Jacobs, Ian
AU - Song, Honglin
AU - Pharoah, Paul D P
AU - Iversen, Edwin S.
AU - Marks, Jeffrey R.
AU - Pike, Malcolm C.
AU - Gayther, Simon A.
AU - Cunningham, Julie M.
AU - Goodman, Marc T.
AU - Schildkraut, Joellen M.
AU - Chenevix-Trench, Georgia
AU - Berchuck, Andrew
AU - Sellers, Thomas A.
N1 - A10119, Cancer Research UK, United KingdomA10124, Cancer Research UK, United KingdomCA-58860, NCI NIH HHS, United StatesCA-92044, NCI NIH HHS, United StatesCA14089, NCI NIH HHS, United StatesCA16056, NCI NIH HHS, United StatesCA17054, NCI NIH HHS, United StatesCA61132, NCI NIH HHS, United StatesCA63464, NCI NIH HHS, United StatesCA71766, NCI NIH HHS, United StatesN01 PC035137, NCI NIH HHS, United StatesN01-PC-67010, NCI NIH HHS, United StatesN01-PC35137, NCI NIH HHS, United StatesP50-CA105009, NCI NIH HHS, United StatesR01 CA 86888, NCI NIH HHS, United StatesR01 CA058598-12, NCI NIH HHS, United StatesR01 CA114343, NCI NIH HHS, United StatesR01 CA61107, NCI NIH HHS, United StatesR01 CA87538, NCI NIH HHS, United StatesR01-CA-76016, NCI NIH HHS, United StatesR01-CA54419, NCI NIH HHS, United StatesR01-CA58598, NCI NIH HHS, United StatesR01CA112523, NCI NIH HHS, United StatesR03-CA113148, NCI NIH HHS, United States, Cancer Research UK, United Kingdom, Department of Health, United Kingdom
PY - 2010/2
Y1 - 2010/2
N2 - Aberrant glycosylation is a well-described hallmark of cancer. In a previous ovarian cancer case control study that examined polymorphisms in 26 glycosylation-associated genes, we found strong statistical evidence (P = 0.00017) that women who inherited two copies of a single-nucleotide polymorphism in the UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase, GALNT1, had decreased ovarian cancer risk. The current study attempted to replicate this observation. The GALNT1 single-nucleotide polymorphism rs17647532 was genotyped in 6,965 cases and 8,377 controls from 14 studies forming the Ovarian Cancer Association Consortium. The fixed effects estimate per rs17647532 allele was null (odds ratio, 0.99; 95% confidence interval, 0.92-1.07). When a recessive model was fit, the results were unchanged. Test for hetero geneity of the odds ratios revealed consistency across the 14 replication sites but significant differences compared with the original study population (P = 0.03). This study underscores the need for replication of putative findings in genetic association studies. ©2010 AACR.
AB - Aberrant glycosylation is a well-described hallmark of cancer. In a previous ovarian cancer case control study that examined polymorphisms in 26 glycosylation-associated genes, we found strong statistical evidence (P = 0.00017) that women who inherited two copies of a single-nucleotide polymorphism in the UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase, GALNT1, had decreased ovarian cancer risk. The current study attempted to replicate this observation. The GALNT1 single-nucleotide polymorphism rs17647532 was genotyped in 6,965 cases and 8,377 controls from 14 studies forming the Ovarian Cancer Association Consortium. The fixed effects estimate per rs17647532 allele was null (odds ratio, 0.99; 95% confidence interval, 0.92-1.07). When a recessive model was fit, the results were unchanged. Test for hetero geneity of the odds ratios revealed consistency across the 14 replication sites but significant differences compared with the original study population (P = 0.03). This study underscores the need for replication of putative findings in genetic association studies. ©2010 AACR.
U2 - 10.1158/1055-9965.EPI-09-0861
DO - 10.1158/1055-9965.EPI-09-0861
M3 - Article
C2 - 20142253
SN - 1055-9965
VL - 19
SP - 600
EP - 604
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 2
ER -